New Challenges in Ocular Drug Delivery

Topic Information

Dear Colleagues,

The clinical treatment of diseases affecting the eye globe, and specifically the retina and posterior eye segment, is often hindered by the physiological protection structures and mechanisms of the organ, as well as by the unsuitable physico-chemical features of the active molecules. Intravitreal injections of drugs and monoclonal antibodies is at present the most common therapeutic procedure to reach the retinal area, however being associated to a high risk of side effects, apart than requiring the intervention of a physician. One of the ‘dream goals’ in this field still remains reaching the retinal area using a simple topically applied eye-drop formulation. Researches in the last years have progressively made available new strategies and technologies to overcome the problems that hinder an efficacious ocular drug bioavailability, leading to even more safe, easy-to-use and highly compliant therapeutic means. Controlled release as well as nanomedicine approaches, mainly based on polymeric or lipid matrices, are among the most largely explored strategies to pursue this aim. The Topic is aimed at collecting the most recent experiences from worldwide laboratories to make an update of the state-of-the-art and open new perspectives toward innovative and effective ocular therapies. In particular, studies dealing with biotech products and gene material will be welcommed, since the association of new therapeutic means with personalized treatments is ready to become the most exciting ambition for the next future of ophthalmology.

Prof. Dr. Rosario Pignatello
Dr. Hugo Almeida
Dr. Debora Santonocito
Dr. Carmelo Puglia
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Journal of Nanotheranostics jnt	-	-	2020	15.0 days *	1000 CHF	Submit
Nanomaterials nanomaterials	5.719	6.6	2011	12.7 Days	2600 CHF	Submit
Pharmaceuticals pharmaceuticals	5.215	4.0	2004	15.6 Days	2200 CHF	Submit
Pharmaceutics pharmaceutics	6.525	6.0	2009	15.9 Days	2600 CHF	Submit
Journal of Functional Biomaterials jfb	4.901	10.0	2010	11.9 Days	2000 CHF	Submit

* Median value for all MDPI journals in the second half of 2022.

Published Papers (1 paper)

Order results

Content type Publication Date

Result details

Normal Extended Compact

Journals

All JNT Nanomaterials Pharmaceuticals Pharmaceutics JFB

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

Error

Oops... you haven't selected anything for export.

Ok

clear

attachment

Supplementary material:
Supplementary File 1 (ZIP, 260 KiB)

get_app

subject

View online as:
Abstract Page
Full-Text HTML

Open AccessArticle

Travoprost Liquid Nanocrystals: An Innovative Armamentarium for Effective Glaucoma Therapy

by

Mohamed A. El-Gendy

,

Mai Mansour

,

Mona I. A. El-Assal

,

Rania A. H. Ishak

and

Nahed D. Mortada

Pharmaceutics 2023, 15(3), 954; https://doi.org/10.3390/pharmaceutics15030954 - 15 Mar 2023

Viewed by 371

Abstract

To date, the ophthalmic application of liquid crystalline nanostructures (LCNs) has not been thoroughly reconnoitered, yet they have been extensively used. LCNs are primarily made up of glyceryl monooleate (GMO) or phytantriol as a lipid, a stabilizing agent, and a penetration enhancer (PE). [...] Read more.

To date, the ophthalmic application of liquid crystalline nanostructures (LCNs) has not been thoroughly reconnoitered, yet they have been extensively used. LCNs are primarily made up of glyceryl monooleate (GMO) or phytantriol as a lipid, a stabilizing agent, and a penetration enhancer (PE). For optimization, the D-optimal design was exploited. A characterization using TEM and XRPD was conducted. Optimized LCNs were loaded with the anti-glaucoma drug Travoprost (TRAVO). Ex vivo permeation across the cornea, in vivo pharmacokinetics, and pharmacodynamic studies were performed along with ocular tolerability examinations. Optimized LCNs are constituted of GMO, Tween^® 80 as a stabilizer, and either oleic acid or Captex^® 8000 as PE at 25 mg each. TRAVO-LNCs, F-1-L and F-3-L, showed particle sizes of 216.20 ± 6.12 and 129.40 ± 11.73 nm, with EE% of 85.30 ± 4.29 and 82.54 ± 7.65%, respectively, revealing the highest drug permeation parameters. The bioavailability of both attained 106.1% and 322.82%, respectively, relative to the market product TRAVATAN^®. They exhibited respective intraocular pressure reductions lasting for 48 and 72 h, compared to 36 h for TRAVATAN^®. All LCNs exhibited no evidence of ocular injury in comparison to the control eye. The findings revealed the competence of TRAVO-tailored LCNs in glaucoma treatment and suggested the potential application of a novel platform in ocular delivery. Full article

(This article belongs to the Topic New Challenges in Ocular Drug Delivery)

►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

 

Error

Oops... you haven't selected anything for export.

Ok

clear

Displaying articles 1-1